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Introduction
Among its multitude of  functions, the heathy liver produces the primary fuel glucose and the alternative 
fuel ketone bodies to furnish peripheral organs with nutrients needed to meet energy requirements. Long-
term overnutrition, common with Western-style diets, often provokes the development of  nonalcoholic 
fatty liver disease (NAFLD), a condition affecting 30% of  adults in the United States in which ectopic 
fat accumulates in otherwise normal hepatocytes, and hepatic glucose production (HGP) becomes less 
responsive to the inhibitory effects of  insulin (1–5). Through incompletely understood mechanisms, as high 
as 10% of  those with NAFLD progress to nonalcoholic steatohepatitis (NASH), a condition characterized 
by hepatocyte injury, hepatic inflammation, and fibrosis, which predisposes individuals to cardiovascular 
disease, and can progress further to cirrhosis and hepatocellular carcinoma (1). Understanding disease 
pathogenesis and markers for the progression NAFLD to NASH represent critical areas of  focus in efforts 
to counter the developing healthcare crisis stemming from this epidemic.
While several molecular targets are under consideration, mechanistic underpinnings of the 
transition from uncomplicated nonalcoholic fatty liver disease (NAFLD) to nonalcoholic 
steatohepatitis (NASH) remain unresolved. Here we apply multiscale chemical profiling 
technologies to mouse models of deranged hepatic ketogenesis to uncover potential NAFLD driver 
signatures. Use of stable-isotope tracers, quantitatively tracked by nuclear magnetic resonance 
(NMR) spectroscopy, supported previous observations that livers of wild-type mice maintained 
long term on a high-fat diet (HFD) exhibit a marked increase in hepatic energy charge. Fed-state 
ketogenesis rates increased nearly 3-fold in livers of HFD-fed mice, a greater proportionate increase 
than that observed for tricarboxylic acid (TCA) cycle flux, but both of these contributors to overall 
hepatic energy homeostasis fueled markedly increased hepatic glucose production (HGP). Thus, 
to selectively determine the role of the ketogenic conduit on HGP and oxidative hepatic fluxes, we 
studied a ketogenesis-insufficient mouse model generated by knockdown of the mitochondrial 
isoform of 3-hydroxymethylglutaryl-CoA synthase (HMGCS2). In response to ketogenic 
insufficiency, TCA cycle flux in the fed state doubled and HGP increased more than 60%, sourced by 
a 3-fold increase in glycogenolysis. Finally, high-resolution untargeted metabolomics and shotgun 
lipidomics performed using ketogenesis-insufficient livers in the fed state revealed accumulation of 
bis(monoacylglycero)phosphates, which also accumulated in livers of other models commonly used 
to study NAFLD. In summary, natural and interventional variations in ketogenesis in the fed state 
strongly influence hepatic energy homeostasis, glucose metabolism, and the lipidome. Importantly, 
HGP remains tightly linked to overall hepatic energy charge, which includes both terminal fat 
oxidation through the TCA cycle and partial oxidation via ketogenesis.
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As a fat oxidation spillover pathway most actively engaged in carbohydrate-restricted settings, ketogen-
esis is not commonly considered among the influences of  NAFLD pathogenesis. Normally during the post-
absorptive state, nonesterified fatty acids (NEFAs) generated by adipose tissue lipolysis are proportionally 
catabolized within the mitochondrion through β-oxidation, generating acetyl-CoA. In hepatocytes, mito-
chondrial β-oxidation–derived acetyl-CoA is either terminally oxidized via the tricarboxylic acid (TCA) 
cycle or diverted to ketogenesis for generation of  the energy-rich ketone bodies acetoacetate (AcAc) and 
D-β-hydroxybutryate (βOHB) for export. Ketone bodies are generated from fatty acid–derived acetyl-CoA 
through a series of  reactions requiring the fate-committing mitochondrial isoform of  3-hydroxymethyl-
glutaryl (HMG)-CoA synthase (HMGCS2) that generates HMG-CoA, which is converted to AcAc by 
mitochondrial HMG-CoA lyase (HMGCL). AcAc is reduced to βOHB by the mitochondrial and NAD+/
NADH–dependent enzyme βOHB dehydrogenase (BDH1). Ketogenesis is relatively restricted to hepato-
cytes due to selective HMGCS2 in these cells, and while the reaction catalyzed by HMGCL is also required 
for ketogenesis, it is not uniquely fate-committing because the HMGCL step is downstream of  that cata-
lyzed by HMGCS2, and HMGCL is also indispensable for leucine catabolism, in which HMGCS2 does 
not play a role (6). In the cytoplasm, the HMGCS1 isoform catalyzes the same condensation reaction as 
that catalyzed by HMGCS2 in mitochondria, and the former is a key enzyme in the mevalonate biosyn-
thetic pathway, preceding the step catalyzed by HMG-CoA reductase. After export from mitochondria and 
from hepatocytes into the circulation, ketone bodies are highly efficient substrates for extrahepatic tissues 
with the potential to support up to 20% of  total human energy expenditure (7–9).
While playing a relatively minor role in the normal fed state, the mitochondrial ketogenic conduit may 
be an important consideration in NAFLD because a hallmark of  NAFLD is an abundance of  fat extracted 
by the liver that is mismatched to mitochondrial capability to terminally dispose it. Lipolytic excess, coupled 
with unchecked hepatic lipogenesis, leads not only to ectopic fat accumulation in the hepatocyte, but places 
an excessive fat-processing burden on the hepatic mitochondrion (10). Increased oxidative flux through 
the TCA cycle has been associated with NAFLD (10–13). Increased TCA cycle flux provides a terminal 
fate for a portion of  excess fat but does not fully compensate for the load delivered to the hepatocyte, and 
TCA cycle flux increases also predispose to oxidative stress. By disposing a product of  hepatic β-oxidation, 
acetyl-CoA, ketogenesis prevents the need for hepatic terminal fat oxidation, offloading a substantial frac-
tion of  reducing equivalents from the liver to extrahepatic tissues, and thus ketogenesis could be an ideal 
pathway to clear excess lipid. In spite of  this, ketogenesis is underutilized in prediabetic obesity, in that 
through both fed and fasting states, ketogenesis is inadequately tuned to available fat, and is often dimin-
ished relative to lean controls (12–18). Many of  these observations were collected under fasting conditions 
in which ketogenesis is most active, but ketogenesis during nonfasting periods is quite variable, and could 
be an under-utilized fat disposal conduit, attenuated by metabolic and hormonal control of  HMGCS2 (6).
Recently, analysis of  mice with HMGCS2 deficiency in the carbohydrate-laden, high-fat diet–fed 
(HFD-fed) state revealed that ketogenic insufficiency could model the evolution of  uncomplicated NAFLD 
to NASH (19). Here, we apply dual isotope tracer nuclear magnetic resonance (NMR) spectroscopy, iso-
tope-label-tracking untargeted metabolomics using high-resolution liquid chromatography/mass spectrom-
etry (LC/MS), and shotgun lipidomics studies of  this ketogenesis-insufficient mouse model in the carbo-
hydrate-laden fed state, prior to the onset of  injury and inflammation, to reveal significant derangements in 
glucose, TCA cycle, and lipid metabolism incurred by variations of  ketogenic capacity.
Results
Long-term HFD increases central hepatic metabolic fluxes. We and others have posed that ketogenesis in liv-
ers of  obese humans and rodents insufficiently matches the fat delivered to it (6). To formally quantify 
metabolic fluxes in livers of  mice with metabolic features of  NAFLD, we fed wild-type C57BL/6 mice a 
long-term (40-week-old male mice, 35 weeks on 60% kcal fat diet) HFD, comparing them to age-matched 
chow-fed controls. As expected, greater than 70% increase in body weight, compared with controls, and 
histological evidence of  profound steatosis were uniquely observed in the HFD-fed animals (Supplemen-
tal Figure 1, A–C; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.99762DS1). We then performed 60-minute portal vein perfusions of  mice from both groups in the 
fed state, using oxygenated Krebs-Henseleit buffer (19–21) lacking glucose, but containing unlabeled 0.2 mM 
sodium octanoate (exogenous fat source), 3% 2H2O, and 0.2 mM sodium [U-
13C]propionate, and collected 
the hepatic venous effluent. After metabolite extraction and quantification using 1H-NMR (Supplemental 
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Figure 2A), the hepatic 13C/2H–labeled glucose pool was derivatized to monoacetone glucose, from which 
2H and 13C signals were collected, allowing hepatic oxidative fluxes to be quantified (Supplemental Figure 2, 
B and C) (10, 22). Total HGP by livers of  HFD-fed mice was increased nearly 3-fold (3.07 ± 0.16 μmole/min 
vs. 1.19 ± 0.21 μmole/min tissue in controls, n = 6/group, P < 0.001; Figure 1A). All 3 contributors to HGP 
(glycogenolysis, glycerol, and phosphoenolpyruvate [PEP]) were increased in livers of  HFD-fed mice, such 
that relative contributions of  each to all of  HGP were normal (Supplemental Figure 3, A–D). Moreover, 
ketogenesis was similarly increased (1.52 ± 0.19 μmole/min vs. 0.58 ± 0.08 μmole/min tissue in controls, 
n = 6/group, P = 0.001; Figure 1B), similar to previous observations in HFD-fed rodents (10). Interestingly, 
perfusions performed in the absence of  octanoate in the perfusion buffer revealed that endogenous liver fat 
alone confers a 3-fold increase in ketogenesis for livers of  HFD-fed animals (0.032 ± 0.003 μmole/min vs. 
0.011 ± 0.003 μmole/min tissue in controls, n = 6–9/group, P = 0.001; Figure 1C). TCA cycle flux was 
modestly but not significantly increased in octanoate-containing perfusions of  mice maintained on the HFD, 
compared with the chow diet cohort (Figure 1D). Nonetheless, livers of  HFD-fed animals were indeed in a 
high-energy state, as gluconeogenesis, pyruvate cycling, and anaplerosis, in absolute terms and normalized 
to TCA flux, were all increased in livers of  HFD-fed mice (Supplemental Figure 3, C–F), and octanoate 
consumption was increased by more than 2-fold in livers of  HFD-fed mice (1.21 ± 0.16 μmole/min vs. 0.56 
± 0.15 μmole/min tissue in controls, n = 6/group, P = 0.005; Figure 1E).
As β-oxidation of  octanoate yields 4 acetyl-CoA units, we imputed the relative allocations of  octanoate-
derived acetyl-CoA. While terminal oxidation through the TCA cycle represents a minor fate (≤5%) for the 
carbon available from octanoate-derived acetyl-CoA in either diet setting in 40-week-old mice, ketogenesis is 
the major carbon consumer and energy conduit for both HFD-fed (64%) and chow-fed (53%) mice (Figure 
1F). Much of  the unaccounted fates for octanoate likely includes AcAc (which is not quantified using this 
analytical approach), but acylcarnitines and other incompletely oxidized intermediates also comprise the 
balance of  carbon consumption from β-oxidation, as esterification and storage of  the medium-chain fatty 
acid octanoate is minimal (23). Notably, while the livers of  HFD-fed mice exhibited 2-fold greater octano-
ate uptake, the corresponding fractional component dedicated to ketogenesis was only approximately 20% 
Figure 1. Increased hepatic oxidative fluxes provoked 
by sustained high-fat diet feeding in wild-type mice. 
(A) Glucose production and (B) βOHB production by 
livers of age-matched mice fed standard chow versus 
60% kcal fat diet for 35 weeks, quantified by 1H-NMR 
of hepatic venous effluent from 60-minute portal vein 
perfusion using an oxygenated buffer containing 0.2 
mM unlabeled sodium octanoate as exogenous fat, 
3% 2H2O, and 0.2 mM sodium [U-
13C]propionate. (C) 
βOHB production rates in separate perfusions using 
an oxygenated buffer that was otherwise identical 
but lacked an exogenous fat source. (D) TCA cycle flux 
rates, quantified by 13C-NMR of monoacetone [13C/2H]
glucose derivatized from hepatic venous effluent 
13C/2H–labeled glucose, from perfusions using an oxy-
genated buffer containing 0.2 mM unlabeled sodium 
octanoate, 3% 2H2O, and 0.2 mM sodium [U-
13C]pro-
pionate. (E) Octanoate consumption rates by livers of 
mice described and analyzed as in A and B. (F) Imputed 
balances of octanoate-derived acetyl-CoA fates, based 
on octanoate consumption and measured disposal of 
acetyl-CoA through the TCA cycle and βOHB produc-
tion. Note that little octanoate is esterified to glycerol, 
and much of the unaccounted fraction is attributable 
to AcAc. HFD, high-fat diet. n = 6/group. **P < 0.01; 
***P < 0.001; ****P < 0.0001. ns, not significant by 
Student’s t test.
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greater than that observed for the control group. Therefore, while insufficient to clear the lipid load extracted 
and stored, ketogenesis in obese, HFD-fed wild-type mice is increased in absolute terms, from either exog-
enous or endogenous fat.
Ketogenic insufficiency reprograms central hepatic glucose metabolism. Given these observations, we hypoth-
esized that ketogenesis may be a dynamically regulated metabolic node, which can feed back to modulate 
normal hepatic glucose and oxidative metabolic homeostasis. To determine the effects of  genetically engi-
neered ketogenic insufficiency, we studied Hmgcs2 antisense oligonucleotide–treated (Hmgcs2-ASO-treated) 
and control-ASO-treated standard-chow-fed, 12- to 16-week-old male mice, 6–8 weeks after initiation of  
ASO knockdown. This approach results in greater than 90% loss of  hepatic HMGCS2 protein within 3 
weeks of  ASO initiation, and HFD-induced hepatocellular injury and inflammation (19). Importantly, 
however, standard-chow-fed Hmgcs2-ASO-treated mice do not exhibit hepatocellular injury or inflamma-
tion. Therefore, to develop signatures that precede and thus prospectively contribute to metabolically driven 
hepatitis disease progression, we performed chemical profiling studies using these mice in the standard-
chow-fed state. To formally quantify central metabolic fluxes in the livers of  these animals, we first per-
formed 60-minute portal vein perfusions using oxygenated glucose-free buffer containing unlabeled 0.2 mM 
sodium octanoate and 3% 2H2O. Both sodium [U-
13C]propionate–containing (0.2 mM) and propionate-free 
perfusions were performed independently to confirm the absence of  effect of  this propionate concentration 
on HGP, its contributing pathways, or ketogenesis (24). Consistent with our published observations using 
alternative methods in the same model, ketogenesis was attenuated 10-fold in livers of  Hmgcs2-ASO-treated 
mice (in the presence of  propionate, 0.03 ± 0.00 μmole/min/g vs. 0.36 ± 0.07 μmole/min/g tissue in 
Hmgcs2- and control-ASO-treated mice, respectively, n = 10–13/group, P < 0.001; Figure 2A). As expected, 
although ketogenesis was still measurable, exclusion of  the exogenous octanoate fat source in the perfusion 
buffer diminished ketogenesis by nearly 20-fold in control animals, and ketogenesis derived from endog-
enous fat was undetectable by NMR in livers of  ketogenesis-insufficient animals (Figure 2B). Excluding 0.2 
mM [13C]propionate had no significant effect on octanoate-supported ketogenesis in either animal cohort 
(0.04 ± 0.01 μmole/min/g vs. 0.53 ± 0.09 μmole/min/g tissue in Hmgcs2- and control-ASO-treated mice, 
respectively, n = 6–10/group, P < 0.002), and including insulin (10 μU/ml) in the perfusion buffer also 
had no significant effect on ketogenesis in either group (0.07 ± 0.02 μmole/min/g vs. 0.42 ± 0.12 μmole/
min/g tissue in Hmgcs2- and control-ASO-treated mice, respectively, n = 4/group, P = 0.03; Figure 2A). 
Thus, Hmgcs2-ASO-treated mice are ketogenesis insufficient, irrespective of  whether or not exogenous fat 
is delivered to the liver.
Proton NMR revealed a 65% increase of  HGP in livers of  fed-state ketogenesis-insufficient animals 
in the presence of  0.2 mM sodium [U-13C]propionate (1.01 ± 0.12 μmole/min/g vs. 0.61 ± 0.09 μmole/
min/g tissue in Hmgcs2- and control-ASO-treated mice, respectively, n = 12–13/group, P < 0.02; Figure 
2C), and excluding propionate had no significant effect on glucose production rate (1.14 ± 0.12 μmole/
min/g vs. 0.73 ± 0.09 μmole/min/g tissue in Hmgcs2- and control-ASO-treated mice, respectively, n = 
6–10/group, P < 0.02). As expected, 10 μU/ml insulin decreased HGP by more than 60% in both groups 
of  animals (1.01 ± 0.12 vs. 0.35 ± 0.03, n = 4–13/group, in insulin-free and insulin-containing perfusions, 
respectively, in Hmgcs2-ASO-treated animals, P = 0.01; and 0.59 ± 0.21 vs. 0.25 ± 0.06, n = 4–12/group, P 
< 0.01, in insulin-free and insulin-containing perfusions, respectively, in control-ASO-treated mice; Figure 
2C). In the absence of  insulin, glycogenolytic flux was increased nearly 4-fold in livers of  ketogenesis-insuf-
ficient animals (0.58 ± 0.1 μmole/min/g vs. 0.15 ± 0.03 μmole/min/g in Hmgcs2- and control-ASO-treated 
mice, respectively, n = 10–11/group, P < 0.001; Figure 2D), an effect that was also independent of  the pres-
ence of  [13C]propionate in the perfusion buffer. Insulin decreased glycogenolytic flux by 5-fold (0.12 ± 0.01 
μmole/min/g vs. 0.02 ± 0.01 μmole/min/g, n = 4/group, P < 0.001) in control-ASO-treated animals, and 
glycogenolytic flux was attenuated by insulin to a similar magnitude for Hmgcs2-ASO animals (Figure 2D). 
Fluxes of  glycerol-derived HGP were modestly, but not significantly diminished by the inclusion of  either 
[13C]propionate, insulin, or both, but were not different between Hmgcs2- and control-ASO-treated mice 
(Figure 2E). HGP absolute flux rates from PEP also showed no [13C]propionate- or HMGCS2-dependent 
effect, but insulin modestly attenuated PEP flux in both groups (Figure 2F). Taken together, irrespective 
of  the presence or absence of  [13C]propionate, in the fed state, glycogenolysis dominated HGP in livers 
of  ketogenesis-insufficient animals (58% of  HGP, versus 23% of  HGP in controls, P < 0.001; Figure 2G), 
whereas in livers of  control animals, glycerol- and PEP-derived gluconeogenesis dominated HGP. Insulin 
attenuated glycogen’s contribution to HGP in livers of  both ketogenesis-insufficient and control animals, 
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but even in the presence of  insulin, glycogenolysis sourced HGP to a much greater extent in liver of  keto-
genesis-insufficient animals than those of  controls (34% vs. 10% in controls, n = 4/group, P < 0.004).
Because ketogenic insufficiency was associated with increased glycogenolysis, we quantified hepatic gly-
cogen pool sizes using livers from mice not undergoing portal vein perfusions. In livers harvested from age-, 
Figure 2. Ketogenesis-insufficient mice exhibit augmented glycogen-sourced hepatic glucose production. (A) βOHB production quantified using hepatic 
venous effluent from 60-minute portal vein perfusions using oxygenated buffers containing 0.2 mM unlabeled sodium octanoate and 3% 2H2O, in the 
absence (–) or presence (+) of sodium [U-13C]propionate (0.2 mM) or insulin (10 μU/ml). (B) βOHB production in the absence (–) or presence (+) of sodium 
octanoate (0.2 mM) from 60-minute portal vein perfusions using oxygenated buffers. The first 2 bars on the left are presented for comparison and represent 
the same data as those presented in the middle 2 bars in panel A. (C) Glucose production, (D) glycogenolysis flux, (E) glycerol-supported flux to gluconeo-
genesis, and (F) phosphoenolpyruvate–supported (PEP-supported) flux to gluconeogenesis quantified as described for panel A. (G) Relative contributions 
of glycogen, glycerol, and PEP to hepatic glucose production, derived from data presented in panels C–F. (H) Hepatic glycogen concentrations in random-fed 
(collected at 10 am) mice. n = 6–13/group. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. ns, not significant by 2-way ANOVA with Tukey’s or Bonferro-
ni’s post hoc test, or Student’s t test as appropriate. Boxed values correspond to the effect of 10 μU/ml insulin in the presence of [13C]propionate, compared 
with the absence of insulin in the presence of [13C]propionate. ND, none detected.
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strain-, and sex-matched mice under random-fed conditions without restriction to food supply, the glycogen 
pool was surprisingly increased nearly 60% in livers of  ketogenesis-insufficient mice (40.7 ± 2.6 μg/mg liver 
vs. 25.6 ± 3.0 μg/mg liver in Hmgcs2- and control-ASO-treated mice, respectively, n = 8/group, P < 0.01; Fig-
ure 2H). To determine if  these collective observations could be linked to the function of  the primary enzymat-
ic mediators of  glycogen turnover, glycogen phosphorylase and synthase, we used Western blots to quantify 
the abundances of  both total and phosphorylated fractions of  these enzymes in livers of  animals in the ran-
dom-fed and postperfusion states, because hormonally regulated phosphorylation of  these enzymes activate 
or inhibit their specific activities, respectively (3). In the random-fed state, the abundance of  the liver-specific 
isoform of glycogen phosphorylase in its phosphorylated (active) state (p-PYGL) was significantly diminished 
more than 50% (n = 4/group, P = 0.03; Figure 3, A and B) in the livers of  ketogenesis-insufficient animals. 
Most of  this decrease appeared to be attributable to an approximately 40% decrease in the abundance of  the 
total PYGL pool (n = 4/group, P = 0.007; Figure 3, A and C), such that the diminution of  p-PYGL, normal-
ized to the total PYGL pool, did not meet statistical significance (Figure 3D). After perfusion, there were no 
Figure 3. Diminished abundances of 
phosphorylated and total glycogen 
phosphorylase in livers of random-fed, 
but not postperfused ketogenesis-
insufficient mice. Immunoblots for the 
phosphorylated (serine 15, activated) 
version of the liver isoform of glycogen 
phosphorylase (p-PYGL), total PYGL, 
HMGCS2, and actin, acquired from 
protein lysates from livers of animals 
in the random-fed state (A–D) or livers 
acquired at the end of a 60-minute 
metabolic perfusion using octanoate-
containing oxygenated buffer (E–H). 
Densitometric quantifications of p-PYGL 
(B and F), total PYGL (C and G), and 
the p-PYGL/PYGL ratio (D and H), all 
normalized to actin. n = 4/group. *P < 
0.05; **P < 0.01. ns, not significant by 
Student’s t test.
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significant differences in p-PYGL or PYGL, and the total PYGL pool size became equalized (Figure 3, E–H). 
Finally, there were no differences in the phosphorylated fractions or total pool sizes of  glycogen synthase (GS) 
in the random-fed or postperfusion states (Supplemental Figure 4). Taken together, these quantifications of  
glycogenolysis flux, hepatic glycogen pool sizes, and enzyme abundance all suggest that livers of  ketogenesis-
insufficient mice are poised to store hepatic glycogen, likely due to diminished PYGL activity, but that in 
perfused livers, glycogenolysis from these larger pools becomes unrestrained. These collective observations are 
also consistent with the very mild hyperglycemia and normal insulinemia that we previously observed in these 
animals in vivo, contrasted here with substantially increased hepatic glucose output due to glycogenolysis in 
the ketogenesis-insufficient perfused liver (19).
Ketogenic insufficiency increases TCA cycle flux, unmatched by gluconeogenesis, pyruvate cycling, and anaplerosis. 
Given the intimate metabolic connection between hepatic ketogenesis and TCA cycle flux, and in turn the 
tight coupling among TCA cycle flux, hepatic anaplerosis/cataplerosis, and PEP-derived gluconeogenesis, 
13C-NMR signal magnitudes were obtained from monoacetone [13C/2H]glucose derived from hepatic venous 
effluent 13C/2H–labeled glucose from portal vein perfusions, allowing quantification of  hepatic oxidative 
fluxes. Livers of  ketogenesis-insufficient mice exhibited a 2-fold increase in TCA cycle flux in the fed state 
(0.25 ± 0.05 μmole/min/g vs. 0.12 ± 0.02 μmole/min/g in Hmgcs2- and control-ASO-treated mice, respec-
tively, n = 10–11/group, P < 0.03; Figure 4A). To confirm that this marked increase could not be attributed 
to the relative absence of  ketone bodies themselves, portal vein perfusions were also performed using buffers 
that also contained freshly prepared either 1 mM βOHB/0.1 mM AcAc, or separately, 1 mM AcAc/0.1 mM 
βOHB. In either mitochondrial redox potential condition, TCA cycle flux remained increased in livers of  
ketogenesis-insufficient animals (Figure 4A), indicating that ketogenic flux impairment, rather than ketone 
bodies themselves, was responsible for the increase in TCA flux. Consistent with expectations given the 
effect of  reduced redox potential, TCA flux was modestly (but significantly with respect to its original value) 
diminished in the 1 mM βOHB/0.1 mM AcAc group, and only in control animals.
Previous observations have indicated that, in the setting of  obesity (compared to lean controls), 
increased hepatic TCA flux is matched by commensurate rises in gluconeogenesis (PEP flux), pyruvate 
Figure 4. Increased TCA cycle flux is unmatched by PEP flux, 
pyruvate cycling, and anaplerosis in livers of ketogenesis-
insufficient animals. (A) TCA cycle flux; and (B) PEP flux, (C) 
pyruvate cycling flux, and (D) anaplerotic flux, all normalized 
to TCA cycle flux, quantified by 2H- and 13C-NMR of monoac-
etone [13C/2H]glucose derivatized from hepatic venous effluent 
13C/2H–labeled glucose from 60-minute perfusions using 
oxygenated buffer that included 0.2 mM unlabeled sodium 
octanoate, 3% 2H2O, and 0.2 mM sodium [U-
13C]propionate, in 
the absence or presence of supplemented unlabeled ketone 
bodies at the indicated concentrations. n = 6–13/group. *P 
< 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 2-way 
ANOVA with Tukey’s post hoc test.
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Figure 5. Acetyl-CoA fates in ketogenic insufficiency. (A) Octanoate consumption rates and (B) derived acetyl-CoA fates of livers of animals per-
fused with 0.2 mM unlabeled octanoate–containing oxygenated perfusion buffer from the experiments whose data are presented in Figures 2–4. 
Note that little octanoate is esterified to glycerol, and much of the unaccounted fraction in controls is attributable to AcAc, while very little of the 
unaccounted fraction can be sourced to AcAc in ketogenic insufficiency. (C) LC-MS/MS measurements of acetyl-CoA from extracts of isolated mito-
chondria, normalized to mitochondrial protein content, or (D) total liver tissue, normalized to tissue mass, from livers harvested from unperfused 
mice. (E–H) Untargeted LC/MS metabolomics from liver extracts derived from portal vein perfusions using oxygenated buffer containing 0.2 mM 
sodium [1,2,3,4-13C4]octanoate. Collections were acquired in the negative-ion mode after chromatographic separation. Isotopologues reflect 
13C incor-
poration in 2-atom units consistent with products from labeled acetyl-CoA export from mitochondria. (E) 3-Oxo-octanoic acid, whose monoisotopic 
mass is 158.0943, putatively assigned to m/z 217.1081 [M+CH3COO]
– (acetylated molecular ions are common under the HILIC mobile phase conditions 
employed); M+0, M+2, M+4, and M+6 isotopologues are equally abundant in both genotypes, suggestive that ketogenic insufficiency does not alter 
this metabolite’s labeling. (F) 3-Oxo-decanoic acid, whose monoisotopic mass is 186.1256, putatively assigned to m/z 245.1393 [M+CH3COO]–; M+0, 
M+2, M+4, M+6, and M+8 isotopologues are equally abundant in both genotypes. (G) Butyryl-CoA, whose monoisotopic mass is 837.1571, putatively 
assigned to m/z 417.5715 [M-2H]2–; M+0 and M+2 isotopologues are equally abundant in both genotypes (parent monoisotopic masses that acquire 
2e– in ionization result in a m/z that is half of the expected monoisotopic mass for the molecular ion). (H) Hydroxybutyryl-CoA, whose monoisotopic 
mass is 853.1520, putatively assigned to m/z 425.5691 [M-2H]2–; M+0, M+2, and M+4, isotopologues are equally abundant in both genotypes. n = 
4–6/group. ***P < 0.001; ****P < 0.0001 by Student’s t test.
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cycling, and anaplerosis, such that the ratios of  each of  these fluxes, normalized to TCA flux, remain rela-
tively constant (10). In our experiments in long-term wild-type HFD-fed animals, these fluxes were elevated 
when normalized to TCA cycle, likely indicating that reducing equivalents from β-oxidation/ketogenesis 
drive increased energy charge (Figure 1 and Supplemental Figure 3F). Intriguingly, in livers of  chow diet–
fed ketogenesis-insufficient animals in the fed state, the increase in TCA flux was not matched by increases 
in PEP flux, pyruvate cycling, or anaplerosis, such that each of  these fluxes becomes significantly dimin-
ished relative to TCA flux (Figure 4, B–D). As observed with regard to TCA flux rates, supplementation of  
ketone bodies did not significantly alter the effects of  ketogenic insufficiency on PEP flux, pyruvate cycling, 
or anaplerosis. Moreover, supplemented ketone bodies did not abrogate the augmentation of  HGP and gly-
cogenolysis in livers of  ketogenesis-insufficient animals, and overall glucose sourcing was not significantly 
altered (Supplemental Figure 5). Taken together, these observations suggest that the relationships between 
anaplerotic/cataplerotic flux and TCA cycle flux vary among metabolic contexts, underscoring the need 
to consider all contributors to hepatic energy charge, particularly in pathological conditions that include 
NAFLD progression to NASH.
Ketogenic insufficiency redistributes mitochondrial acetyl-CoA fates. Increased TCA cycle flux in livers of  
ketogenesis-insufficient animals, even in the fed state, is not unexpected; as long as oxaloacetate pools are 
sufficient, β-oxidation–derived acetyl-CoA, whose pools are tightly regulated in mitochondrial matrix, can 
be diverted to citrate synthase. We hypothesized that citrate synthase flux alone would not account for all 
of  the acetyl-CoA that fails to be incorporated into ketone bodies, even in the fed state. The scope of  unac-
counted acetyl-CoA was first determined by using 1H-NMR to quantify octanoate extracted from perfused 
livers, which revealed a 50% decrease in perfused livers of  ketogenesis-insufficient animals that did not 
quite meet statistical significance (Figure 5A). As expected, allocation of  acetyl-CoA to the TCA cycle was 
relatively increased (from 12% to 33%), and to ketogenesis was markedly decreased (from 54% to 7%) in 
livers of  ketogenesis-insufficient animals (Figure 5B). Thus, the balance of  potentially unaccounted acetyl-
CoA was 74% larger (increased from 34% in controls, to 59%) in livers of  ketogenesis-insufficient animals, 
and furthermore, much of  the unaccounted fraction in controls is attributable to AcAc, while little of  the 
59% unaccounted balance in ketogenic insufficiency will be attributable to AcAc.
To determine the additional fates of  acetyl-CoA, we undertook a multiscale approach. First, we used 
targeted LC-MS/MS to determine that steady-state acetyl-CoA concentrations were increased 2-fold in 
mitochondria isolated from unperfused harvested livers of  ketogenesis-insufficient animals, but were nor-
mal in whole liver tissue (Figure 5, C and D). Second, we applied an isotope-tracking untargeted metabolo-
mics approach to map, across the metabolome, the fates of  0.2 mM sodium [1,2,3,4-13C4]octanoate that was 
delivered via portal vein perfusions (19, 25). m/z ratios corresponding to putative identifications for unla-
beled and incrementally [13C]octanoate-derived isotopologue intermediates of  cytoplasmic lipid biosyn-
thesis (3-oxo-octanoic acid, 3-oxo-decanoic acid, butyryl-CoA, and hydroxybutyryl-CoA) were observed 
equally in liver tissue of  control and ketogenesis-insufficient animals (Figure 5, E–I). The observed iso-
topologue patterns for each of  these 4 intermediates derived from β-oxidation of  [1,2,3,4-13C4]octanoate 
can only arise from futile recycling of  [1,2-13C2]acetyl-CoA into cytoplasmic lipid synthesis, rather than as 
intermediates of  β-oxidation alone or due to direct incorporation of  [1,2,3,4-13C4]octanoate into cytoplas-
mic enzymatic acyl chain–lengthening pathways (26). As there were no differences observed in the labeled 
abundances of  these fatty acid synthetic intermediates in livers of  ketogenesis-insufficient animals, hepatic 
ketone bodies in the fed state may not primarily furnish recycled acetyl-CoA to cytoplasmic lipid synthesis, 
or if  they do, alternative mechanisms for acetyl-CoA mitochondrial efflux into cytoplasmic lipid synthetic 
pathways (i.e., citrate or acetylcarnitine efflux) compensate for ketogenic insufficiency. Finally, the absence 
of  any difference in labeling of  hydroxybutyryl-CoA (e.g, βOHB-CoA; Figure 5H) in livers of  ketogenesis-
insufficient mice suggests that hepatic βOHB-CoA, an intermediate of  lysine catabolism and β-oxidation 
itself, is a poor reporter of  hepatic ketogenesis.
Ketogenic insufficiency and fatty liver states promote marked accumulation of  a canonical late endosomal lipid 
class. To determine how ketogenic insufficiency reprograms the metabolome of  the mouse liver in the 
fed state we performed multiscale analysis through MS-based profiling. First, untargeted high-resolution 
LC/MS metabolomics was performed in livers directly harvested (without perfusion) from control and 
ketogenesis-insufficient mice, detecting 7,949 chemical features, of  which 758 features showed more than 
a 2-fold magnitude change with associated P value less than 0.05 (Supplemental Figure 6A and Sup-
plemental Table 1). Putative identification could be assigned to 105 of  the features using the METLIN 
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database (Supplemental Table 2). Nearly 70% of  the assigned and significantly upregulated metabolites 
were putative hyaluronan, decanamide, peptides, and gangliosides (Figure 6A). Intriguingly, 19  of  the 
noted putative identifications mapped to upregulated phosphatidylglycerol (PG) lipid species in livers of  
ketogenesis-insufficient animals (blue-filled circles in Figure 6A). Therefore, targeted multidimensional 
MS-based shotgun lipidomics (MDMS-SL) was undertaken to formally confirm and quantify numerous 
classes of  lipid species. Notably, livers of  ketogenesis-insufficient animals failed to show class-wide dif-
ferences, compared with livers of  control animals, among TAGs, DAGs, lysophosphatidylethanolamines 
(LPEs), phosphatidylinositols (PIs), lysophosphatidylcholines (LPCs), phosphatidylserines (PSs), phos-
phatidylethanolamines (PEs), ceramides, or sphingomyelins (SMs) (Supplemental Figure 6, B and C). 
However, consistent with the putative identities established by untargeted LC/MS, numerous PG species 
were augmented in livers of  ketogenesis-insufficient animals, which accumulated with increasing duration 
of  ketogenic insufficiency (Figure 6B). Surprisingly, abundances of  PG precursors phosphatidic acid (PA) 
species, and PG biosynthetic products, cardiolipin species (CL), were unaffected (Supplemental Figure 7A 
and Figure 6C). Similarly, abundances of  mRNAs encoding mediators of  PG synthesis and catabolism 
were unchanged between control and ketogenesis-insufficient livers (Supplemental Figure 7, A and B). 
These discrepant observations shifted our attention to a class of  PG structural isomers that are usually 
Figure 6. Accumulation of numerous putative phosphatidylglycerol (PG) species in ketogenesis-insufficient livers. (A) Volcano plot of analyzed untar-
geted metabolomics signals from snap-frozen (unperfused) livers revealed, among numerous up- and downregulated chemical features, 19 upregulated 
m/z ratios mapping to putative PG species. (B) High-resolution shotgun lipidomics (MS1) confirmed progressive accumulation of numerous putative PG 
species in livers of snap-frozen ketogenesis-insufficient livers. (C) Radial plot of molar concentrations of the total pools of putative PG species, their 
precursors, phosphatidic acids (PAs), and their products, cardiolipins (CLs). Each segment radiating from the center represents an individual biological 
replicate. n = 4–5/group. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by 2-way ANOVA with Bonferroni’s post hoc test.
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measured in low abundance, except within late endosomes and lysosomes, the bis(monoacylglycero)phos-
phates (BMPs, also known as lysobisphosphatidic acids) (Figure 7A) (27, 28). Indeed, tandem mass spec-
trometric analysis confirmed that livers of  ketogenesis-insufficient animals accumulated predominantly 
BMP lipid species, rather than PGs (Figure 7B). To assess whether BMPs are accumulating in hepato-
cytes, and not in other neighboring cell types in the liver, we isolated hepatocytes from livers of  ketogene-
sis-insufficient and control animals, confirming that the majority of  BMP species were increased in hepa-
tocytes (Figure 7C). Interestingly, abundance of  the ABHD6 enzyme, capable of  catabolizing BMPs in 
late endosomes, was unchanged between control and ketogenesis-insufficient livers (Supplemental Figure 
7C) (29, 30). While there is relatively little literature regarding BMPs, the most prevalent biological func-
tion reported is the modulation of  cholesterol transport through late endosomes and lysosomes (27, 28). 
Total hepatic cholesterol contents were normal in livers of  ketogenesis-insufficient animals, suggesting 
that (a) BMPs may also play alternate biological functions, and (b) perturbation of  mitochondrial acetyl-
CoA homeostasis via HMGCS2 manipulation may not have a major impact on HMGCS1-dependent 
metabolism (Supplemental Figure 7D). Nonetheless, association of  the BMP lipid class with NAFLD 
progression may be a generalized biomarker, as livers of  db/db mice, and HFD-fed wild-type mice, also 
exhibit increased abundance of  the BMP lipid class, despite normal ketonemia (Figure 7C and Supple-
mental Figure 7, E–H). Taken together, the results show that both ketogenesis-insufficient livers and other 
models of  NAFLD exhibit progressive accumulation of  BMPs, a canonical late endosomal lipid class. 
These observations confirm what we believe to be a novel function of  ketogenesis as a mitochondrial 
pathway that integrates metabolic and signaling pathways among cellular compartments in the fed state, 
thereby coordinating key aspects of  hepatic physiological homeostasis.
Figure 7. MS/MS analysis allows assignment of putative PGs as bis(monoacylglycero)phosphate (BMP) species in multiple models of disordered hepatic 
metabolism, confirmed by tandem MS. (A) Structural isomers phosphatidylglycerol (PG) and bis(monoacylglycero)phosphate (BMP, left); molar concen-
trations of 4 sets of PG/BMP, fully confirmed and speciated using MS/MS (right), revealing progressive accumulation, particularly of BMPs, in livers of 
ketogenesis-insufficient animals. (B) MS confirmation of BMP species abundances in primary cultured hepatocytes. (C) Total PG/BMP pool concentrations 
in livers of wild-type control mice, db/db mice, and wild-type mice maintained on high-fat diet for 8 weeks. C, control ASO; H, Hmgcs2 ASO. n = 4–9/group. 
**P < 0.01; ***P < 0.001; ****P < 0.0001 by Student’s t test or 1-way ANOVA with Tukey’s post hoc test, as appropriate. 
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Discussion
Ketogenesis offers an energetically favorable route for clearance of  fat whose abundance supersedes the 
oxidative disposal capacity of  the hepatic TCA cycle (6). Because ketogenesis is activated in carbohydrate 
restriction and other physiological states in which hepatic glycogen is depleted, this pathway is not com-
monly considered to serve an adaptive role in the carbohydrate-fed state. The findings herein implicate a 
significant role for hepatic ketogenesis in regulating complex metabolic pathways in the liver in a classi-
cally non-ketogenic, hepatic glycogen–replete state. In the fed state, ketogenic insufficiency results in 2 key 
changes in central hepatic metabolic fluxes: (a) doubling of  TCA cycle flux, unaccompanied by commen-
surate increases in gluconeogenesis, pyruvate cycling, or anaplerosis and (b) predisposition to increased 
hepatic glucose production, largely attributable to a marked increase in glycogenolysis. As the liver consti-
tutes only 4% of  body weight and only 10% of  whole-body energy expenditure, doubling hepatic TCA flux 
does not appear to cause an obvious increase in organismal energy expenditure, as ketogenesis-insufficient 
animals maintained on normal chow exhibit normal caloric intake and body weights (19, 31). In fact, it is 
likely that the octanoate-stimulated increase in hepatic TCA cycle flux represents a metabolic compensa-
tion for lost β-oxidation/ketogenesis that ultimately maintains equivalent mitochondrial energy potential 
to that of  control livers.
The primary purposes of  ketogenesis are to (a) support energy harvest from β-oxidation when fatty 
acid supply exceeds energetic demand from the higher-payoff  TCA cycle, (b) reoxidize a portion of  the 
mitochondrial NADH pool through the βOHB dehydrogenase reaction, and (c) after secretion, provide 
an energy source for non-hepatocytes, useful in states of  carbohydrate restriction. Thus, primary effects of  
ketogenesis coordinate hepatocyte metabolic function, but this impact, and its potential ability to dynami-
cally coordinate liver metabolism, is not commonly considered. Livers of  octanoate-fueled ketogenesis-
insufficient mice exhibited augmented TCA flux and elevated mitochondrial acetyl-CoA concentration, 
which together would normally be expected to yield a commensurate rise in gluconeogenesis and anaple-
rosis. ATP is a substrate, and acetyl-CoA is an allosteric activator of  anaplerotic pyruvate carboxylase, 
while endergonic gluconeogenic flux requires 6 moles of  nucleotide triphosphate plus 2 moles of  NADH 
per mole of  glucose produced. Instead, gluconeogenic and anaplerotic fluxes were normal in ketogenesis-
insufficient livers, suggesting that energy charge in ketogenesis-insufficient livers is normal. As a primary 
energy consumer, gluconeogenesis is a surrogate for overall hepatic energy charge, even with significant 
redistributions of  energy economy, such as ketogenic insufficiency, in which over half  of  the energy pro-
duction conduit is lost with ketogenic ablation in the octanoate-fueled liver. Importantly, despite concern 
for confounding and undesired metabolic effects of  using [13C]propionate as a tracer (32), our observations 
are concordant with observations from numerous groups supporting the absence of  effects of  tracer con-
centrations of  propionate on HGP, or its contributing component fluxes (10, 24, 33, 34). Moreover, our 
use of  this method also confirms prior conclusions using similar methods in rodent and human studies 
that fatty liver is in a high energy turnover state (10, 13); specifically, we observed in wild-type mice fed 
an HFD elevations in gluconeogenesis (energy consumer) and ketogenesis (energy producer), despite only 
modest increases in TCA cycle flux. Thus, it may be argued that augmenting ketogenesis to unload excess 
fat could exacerbate the energy surplus of  the fatty liver, and further drive deleterious HGP and oxidative 
stress. The counter-argument to this perspective is that ketogenesis generates fewer reducing equivalents 
than does the TCA cycle (from long-chain fatty acids, ~6 reducing equivalents, compared with ~3 from 
ketogenesis; see ref. 10), and as a higher-capacity conduit, may be an effective mechanism to distribute 
excess reducing equivalents to extrahepatic tissues in a form that can be readily oxidized. Indeed, clinical 
success of  sodium-glucose cotransporter-2 (SGLT2) inhibition, an oral hypoglycemic therapy that increases 
both ketogenesis and HGP, suggests that in select metabolic contexts, ketogenic augmentation may be 
advantageous (35–37).
In addition to increased TCA cycle flux, the ketogenesis-insufficient liver enlists multiple mechanisms to 
maintain normal energy charge, including (a) diminished extraction of  the available fat, (b) maintenance of  
modestly higher steady-state acetyl-CoA concentrations in mitochondria, and (c) disposal of  over half  of  the 
energy stored in fatty acids to destinations not identified by the stable-isotope-tracking NMR and high-res-
olution untargeted metabolomics platforms used herein. Our previous observations indicated medium- and 
short-chain acylcarnitines (quantified using targeted approaches, but unmeasured through this untargeted 
metabolomics platform) are likely conduits for β-oxidation–derived intermediates not terminally disposed 
in the TCA cycle or diverted to ketogenesis (19). Interestingly, high-resolution isotope-tracking untargeted 
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metabolomics studies of  livers perfused with [1,2,3,4-13C4]octanoate did confirm recycling of  mitochondrial 
β-oxidation–derived acetyl-CoA into cytoplasmic lipogenesis, likely mediated through citrate efflux, but this 
was not increased in ketogenesis-insufficient livers. However, ketogenesis-insufficient livers perfused from 
labeled carbohydrate substrates (lactate/pyruvate) previously revealed numerous substantially upregulated 
intermediates linked to de novo lipogenesis metabolites (19). These observations indicate that carbohydrate 
but not octanoate-derived acetyl-CoA is preferentially sourced to lipid in ketogenesis-insufficient livers.
The perfused liver model employed herein confers both experimental limitations and important insights. 
Substrate delivery in this perfusion model does not reflect the physiological fatty acid repertoire sampled by 
hepatocytes in vivo, as the delivery of  the carnitine palmitoyltransferase–independent fat octanoate in the 
livers of  animals maintained in the fed state provokes a convergence of  fat oxidation, ketogenic demand, 
and preexisting glycogen pool sizes not commonly encountered in standard absorptive states. This is likely 
to overemphasize the differences in vivo in the unaccounted acetyl-CoA balances, and result in variations 
among relative contributions to HGP, compared with those collected through in vivo studies. Nonetheless, 
the octanoate perfusion model was employed to specifically reveal the effect of  deranged hepatic mito-
chondrial acetyl-CoA allocation to downstream canonical fates on glucose metabolism, which is likely a 
primarily lesioned regulatory node in the pathogenesis of  NAFLD (10, 13, 18, 38). Moreover, the portal 
vein perfusion model specifically quantifies hepatic metabolism and HGP, unlike in vivo approaches that 
administer tracers via systemic veins and track labeled glucose, which do not exclude the roles of  renal or 
intestinal glucose metabolism.
These experiments revealed an unexpected relationship between hepatic glycogen metabolism and 
ketogenic insufficiency, and while the unconventional platform of  the octanoate-fueled perfusion of  a 
glycogen-loaded liver yielded many of  these observations, experiments using livers obtained from mice in 
the random-fed state also support the impact of  ketogenic insufficiency on glycogen metabolism. Hepatic 
glycogen turnover is primarily controlled by the opposing actions of  insulin-stimulated GS, and PYGL (3). 
Glycogen cycling proceeds from glycogen→G1P⇔G6P⇔G1P→UDPG→glycogen. Via activating alloste-
ric effects on GS, and inhibitory allosteric effects on PYGL, a regulatory role is served by G6P, which is in 
equilibrium with 3-carbon gluconeogenic precursors from glycerol and PEP, as well as glucose itself. Liv-
ers of  ketogenesis-insufficient animals are primed to store glycogen, which may be due in part to reduced 
abundance of  the total pool PYGL, thus diminishing the absolute abundance of  active p-PYGL, but other 
factors may also drive glycogen accumulation. The apparent pool size of  G6P was not altered in livers of  
random-fed ketogenesis-insufficient mice (m/z 259.0224, Supplemental Table 2), limiting the likelihood 
that variations in G6P concentrations drive the observed differences. During perfusions lacking both insulin 
and exogenous glucose, the large glycogen pool in livers of  ketogenesis-insufficient mice was mobilized, 
entirely driving the augmentation of  hepatic glucose production from livers of  ketogenesis-insufficient 
mice compared with control. Insulin markedly diminished glycogenolysis in both control and ketogenesis-
insufficient livers. As GS is the primary insulin-responsive enzyme in hepatic glycogen turnover (39), the 
normal response to insulin suggests that GS function is likely normal. Nonetheless, despite the normal 
proportionate response to insulin, glycogenolysis remained elevated in ketogenesis-insufficient livers in the 
presence of  insulin, indicating that mass action or other unidentified allosteric mediators are unique drivers 
of  glycogenolysis in the perfused ketogenesis-insufficient liver.
Livers with engineered ketogenic insufficiency are prone to HFD-induced hepatocellular injury, necro-
sis, and lobular inflammation. Furthermore, these livers engage de novo lipogenesis from carbohydrate-
derived acetyl-CoA, and have high rates of  glycogen turnover that persist in the presence of  insulin — all 
NASH-like signatures, despite the absence of  hepatic steatosis and insulin resistance in this model (19, 40). 
In select contexts, such as the neonatal period, livers of  ketogenesis-insufficient mice are also steatotic (19). 
Moreover, despite normal hepatic concentrations within the TAG and DAG classes in the adult chow-
fed state, untargeted metabolomics and high-resolution lipidomics studies both revealed remodeling of  
the phospholipidome of  livers of  ketogenesis-insufficient animals, particularly among numerous species 
within the BMP lipid class. Strikingly, BMPs are also elevated in steatotic livers from backgrounds that 
do not exhibit genetically engineered ketogenic insufficiency, but in which ketogenesis is mismatched to 
hepatocellular lipid delivery. Whether BMP accumulation is a pathogenic, adaptive, or bystander signature 
will require further investigation. Nonetheless, BMP enrichment in late endosomes and lysosomes suggests 
engagement of  this cellular compartment in all 3 studied models of  disordered hepatic lipid metabolism, 
confirming that organelles beyond lipid droplets and mitochondria should continue to garner investigation 
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in lipid metabolism NAFLD/NASH and pathogenesis (41). However, given the absence of  overt shifts 
in hepatic cholesterol homeostasis, BMP species may accumulate outside of  normally functioning late 
endosomes and lysosomes in pathological settings. Synthetic BMP pathways are only partially defined, and 
mechanisms governing BMP functional properties are unknown. Normal protein abundance of  monoac-
ylglycerol lipase ABDH6, an enzyme localized to late endosomes/lysosomes that subsumes 90% of  BMP 
catabolism, in livers of  ketogenesis-insufficient mice also suggests ectopic localization of  BMPs within 
metabolically stressed hepatocytes (29, 30). When these results are taken together, it is unclear whether 
BMP accumulation can be attributed to increased synthesis, decreased clearance, or both. As the observa-
tions herein suggest that augmentation of  the BMP species was occasionally linked to conditions in which 
PGs were also modestly expanded, transacylation mechanisms exchanging acyl chains between these 2 
pools may be considered in future investigations (27, 28, 42).
These multiscale observations underscore the need to further develop in humans the relationships 
among acetyl-CoA homeostasis, TCA cycle flux, glucose metabolism, and their relationships to yet unchar-
acterized lipid classes in health and disease. Many of  these indices can be acquired noninvasively, with or 
without imaging modalities, and should be considered as measured endpoints in ongoing trials examin-
ing pharmacological agents and nutritional/exercise interventions that may mitigate deranged metabolism 
and fibrosis in the NAFLD/NASH transition (1, 43). Moreover, ketogenesis itself  may extend beyond a 
biomarker of  NASH progression, and evolve into a target pathway worthy of  prosecution. Enthusiasm for 
therapies that promote ketogenic augmentation, e.g., SGLT2i, is appropriately tempered by concerns for 
morbidity and mortality of  ketoacidosis. Nonetheless, multiple nutritional and pharmacological therapies 
targeted to myriad disease states are accompanied by, and may be reliant upon, the broad and safe dynamic 
range exhibited by hepatic ketogenesis. Thus, it is advisable to consider development of  novel therapies for 
metabolic diseases by cautiously accessing the unique properties of  the ketogenic pathway while attending 
to the feared consequence of  ketoacidosis.
Methods
Reagents. All stable isotope–labeled reagents were obtained from Cambridge Isotopes Laboratories, and 
unless otherwise stated all other chemical reagents and solvents were obtained from Sigma-Aldrich.
Animals. All animal experiments were performed through protocols formally approved by the Institution-
al Animal Care and Use Committees at Sanford Burnham Prebys Medical Discovery Institute-Lake Nona 
and the University of  Minnesota. Male C57BL/6N × C57BL/6J mice were maintained on a standard low-fat 
chow diet, in which 12% of the calories were from fat, 22% from protein, and 66% from carbohydrates (Teklad 
Global 16% Protein Rodent Diet) and were given autoclaved water ad libitum. Lights were off  between 1800 
and 0600 hours in a room maintained at 22°C. For all adult mouse experiments, mice were housed on paper 
bedding in groups of  4 to 5. ASO treatment was initiated in 6-week-old mice by intraperitoneal (i.p.) injec-
tion (25 mg/kg) with murine Hmgcs2-targeted ASOs (Ionis, 191229; 5′-CTGTTTGTCACTGCTGGATG) or 
scrambled sequence control ASOs (Ionis, 141923; 5′-CCTTCCCTGAAGGTTCCTCC) biweekly. For HFD 
studies, wild-type male C57BL/6N × C57BL/6J mice were maintained for the indicated number of  weeks, 
starting at 5–6 weeks of  age, on a diet in which 60% of calories were from fat, 20% from protein, and 20% 
from carbohydrates (D12492; Research Diets). Male Leprdb/Leprdb (db/db) mice (Jackson Labs, stock number 
000697) were studied at 10 weeks of  age.
Portal vein perfusions. Perfusions were performed as previously described (19), and detailed methods 
are provided in Supplemental Material. Briefly, mice were anesthetized with 50 μl of  sodium pentobarbi-
tal (65 mg/ml) administered i.p., and once fully unconscious (approximately 5 minutes following deliv-
ery), the portal vein was exposed and cannulated with a 24-gauge catheter needle, the abdominal aorta 
and inferior vena cava cut, and the catheter was firmly tied into the portal vein. The beating heart was 
then exposed by cutting through the diaphragm and thorax. The right atrium was cut to prevent recircula-
tion of  buffer to the liver and to terminate perfusion to the brain. Livers were perfused with our standard 
oxygenated buffer prewarmed to 42°C (determined empirically to counter heat loss in tubing such that 
tissue delivery is maintained at physiological temperature) with a counter-current heat-exchange circuit 
and a recirculating water bath. The buffer delivery was maintained at a rate of  8 ml/min using a peristaltic 
pump for a period of  1 hour. Perfusate effluent from the initial 30 minutes was discarded, and effluent was 
collected from the final 30 minutes of  the procedure. In addition, 1.8-ml collections were made at 30, 40, 
50, and 60 minutes after perfusion initiation.
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NMR methods. All NMR resonances were collected using a Bruker Avance III 600 NMR instrument 
equipped with a CryoProbe. To quantify glucose and βOHB production, and propionate and octanoate 
consumption, aliquots (1.8 ml) of  mouse liver perfusate effluent were collected at 30, 40, 50 and 60 minutes 
after initiation of  the tissue perfusion and stored on ice. These aliquots were frozen following collection and 
processed for NMR analysis at a later time by thawing, removal of  solvent at 45°C under vacuum to dry-
ness, dissolving residual solids in 550 μl of  99.9% 2H2O spiked with 0.3 mM d8-trimethyl-silyl propionate 
(TSP), and collecting 1H-NMR signals under quantitative conditions absent water suppression. Integrated 
intensities of  the α-anomeric proton of  glucose carbon-1, the methyl signal for βOHB, respective α-CH2 
signals from propionate and octanoate, as well as the tri-methyl signal from the reference TSP, when cor-
rected for the number of  protons, can be used to calculate molar concentrations of  the respective substrates. 
Glucose and βOHB production rates can be calculated from the total effluent recovered over the final 30 
minutes of  the perfusion along with the liver weight. Glucose and βOHB production rates were calculated 
as the average from the 4 sample collections. Octanoate consumption can be determined similarly from 
known initial perfusate concentrations (Supplemental Figure 2A). Acetyl-CoA accounting was performed 
by assuming that 4 moles of  acetyl-CoA are produced from each mole of  octanoate consumed. Each mole 
of  βOHB produced consumes 2 moles of  acetyl-CoA, while each turn of  the TCA cycle disposes 1 mole 
of  acetyl-CoA. For all 1H-NMR collections, spectra were collected by conventional pulse-and-collect mea-
surements without water suppression and under quantitative conditions (10-ppm spectral range using ~15 
μs [90°] excitation pulse and 22-second delay between each of  20 transients). NMR methods for glucose 
sourcing and TCA cycle flux analysis are provided in Supplemental Material.
Glycogen extraction and analysis. Mice were anesthetized with 50 μl of  sodium pentobarbital (65 mg/
ml) administered i.p. Once fully unconscious (approximately 5 minutes following delivery), a trans-
verse incision was made through the skin, fascia, and muscular layers of  the lower abdomen, and 
single lobes of  livers were harvested using a liquid nitrogen–chilled Wollenberger-style clamp, and 
immediately flash-frozen in liquid nitrogen. Frozen liver tissue (~50 mg) was transferred to 0.3 ml 
of  30% KOH/H2O solution and maintained at 110°C for 30 minutes. Glycogen with salt was pre-
cipitated by adding 100 μl of  1 M Na2SO4 and 800 μl ethanol and heating to 110°C for 5 minutes. A 
glycogen-rich pellet was obtained by centrifugation at 10,000 g for 5 minutes. Following decanting the 
supernatant, the pellet was dissolved in 0.2 ml H2O followed by a second precipitation with ethanol 
and Na2SO4 and centrifugation. The precipitation was repeated a third time, followed by drying in a 
SpeedVac (ThermoFisher Scientific). The glycogen was then incubated for 3 hours at 40°C in 300 μl of  
a freshly prepared amyloglucosidase solution (0.3 mg/ml [30–60 units/mg protein] in 0.4 M sodium 
acetate buffer, pH 4.8). Following digestion, the sample was dried under vacuum at 45°C and dissolved 
in 0.55 ml 0.3 mM TSP in 99.9% 2H2O. 
1H-NMR spectra were collected under quantitative conditions 
for the α-anomeric proton of  glucose carbon-1 at 5.2 ppm, and confirmation of  glycogen digestion was 
confirmed by the absence of  the glycogen carbon-1 position proton signal at 6.4 ppm.
MS methods for untargeted metabolomics. Mice were anesthetized with 50 μl of  sodium pentobarbital (65 
mg/ml) administered i.p. Once fully unconscious (approximately 5 minutes following delivery), a trans-
verse incision was made through the skin, fascia, and muscular layers of  the lower abdomen, and single 
lobes of  livers were harvested using a liquid nitrogen–chilled Wollenberger-style clamp, and immediately 
flash-frozen in liquid nitrogen. Liver was extracted using previously described methods, with modifications 
(44). Frozen lobules of  liver were lyophilized and extracted using cold (–20°C) 2:2:1 methanol/acetoni-
trile/H2O by 3 cycles of  vortexing, freeze-thawing, and water bath sonication. The samples were then incu-
bated at –20°C for 1 hour followed by a 10-minute centrifugation at maximum speed to remove proteins 
from the solvent. Supernatant was transferred to fresh tubes and evaporated off  in the speed-vac. The dried 
metabolite pellet was reconstituted in 100 μl 1:1 acetonitrile/H2O with the aid of  vortexing and sonication, 
and incubated at 4°C for 1 hour to balance solubility of  metabolites and prevent any remaining protein 
from entering into solution. Samples were then centrifuged (10,000 g for 10 minutes at 4°C) and the super-
natant was used for metabolomics analysis using Phenomenex Luna NH2 column chromatography, and 
negative ionization mode MS using Thermo Q Exactive Plus with a heated electrospray ionization source. 
Detailed methods for untargeted metabolomics are provided in Supplemental Material.
MS methods for shotgun lipidomics. Sample preparation for lipids: frozen liver or isolated hepatocytes (~1 × 
106 cells) were homogenized in ice-cold water with the aid of  2.8- and 1.4-mm zirconium oxide beads in a Pre-
cellys Evolution homogenizer at 4°C–10°C. According to the bicinchoninic acid (BCA) protein concentration 
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result, an appropriate amount of  internal standard mix (containing D14:1 PC, D16:1 PE, D15:0 PG, D14:0 
PS, D14:0 PA, N12:0 SM, 14:0 LPE, 17:0 LPC, T14:0 CL, 13C4 16:0 carnitine, T17:1 TAG, and 1,3-D15:0 
DAG) was added to the homogenate (45). Approximately 130 μl of  homogenate with internal standard mix 
was extracted using a previously described method (46), dried under nitrogen, and diluted to a final concentra-
tion of  approximately 500 fmol/μl lipid. Derivatization and MS were performed using a TSQ Vantage triple 
quadrupole mass spectrometer as described in detail in Supplemental Material.
Acetyl-CoA measurement. Mice were anesthetized with 50 μl of  sodium pentobarbital (65 mg/ml) admin-
istered i.p. Once fully unconscious (approximately 5 minutes following delivery), a transverse incision was 
made through the skin, fascia, and muscular layers of  the lower abdomen, and single lobes of  livers were 
harvested using a liquid nitrogen–chilled Wollenberger-style clamp, and immediately flash-frozen in liq-
uid nitrogen. Livers, or isolated mitochondria (see below) stored at –80°C were lyophilized overnight and 
powdered using a CryoGrinder mortar and pestle (OPS Diagnostics) under liquid nitrogen. Aliquots of  
powdered liver (~5 mg) were prepared for homogenization in various solvents for organic acid, short-chain 
CoA, and pyridine nucleotide assays. Acetyl-CoA was quantified using an Agilent 1290 HPLC/6490 triple 
quadrupole mass spectrometer with electrospray ionization. Calibration standards and liver homogenates 
were prepared in 5% cold trichloroacetic acid spiked with stable isotope–labeled internal standards fol-
lowed by solid-phase extraction (SPE). The methanol extracts from SPE were dried down, reconstituted in 
HPLC buffer, and CoA was quantified by multiple reaction monitoring using LC-MS/MS.
Mitochondrial isolation. Whole livers were excised, washed in ice-cold PBS, weighed, and suspended in 
mitochondrial isolation medium (MIM; 300 mM sucrose, 0.2 mM EDTA, 10 mM HEPES, pH 7.4) con-
taining bovine serum albumin (BSA, 1 mg/ml). The samples were rapidly homogenized on ice by using 
a Glas-Col Dounce homogenizer, and centrifuged at 600 g for 10 minutes at 4°C. The resulting superna-
tant, which contained mitochondria, was spun at 8,000 g for 15 minutes at 4°C. The resultant supernatant 
was discarded, the mitochondrial pellet was resuspended in 10 ml of  ice-cold MIM-BSA, and the sample 
centrifuged again at 8,000 g for 15 minutes at 4°C. The pellet was briefly washed in ice-cold MIM, protein 
quantified by BCA assay, and frozen at –80°C prior to lyophilization.
Gene expression analysis. RNA was purified from whole-liver lysates homogenized in RLT Buffer (Qia-
gen) with 1% 2-mercaptoethanol using the RNeasy Mini Kit (Qiagen) following the manufacturer’s guide-
lines. Reverse transcripts were generated using SuperScript II (Invitrogen), while real-time reverse-transcrip-
tion PCR (RT-PCR) was performed using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) on a 
CFX384 Real-Time System (Bio-Rad). Transcripts were quantified using the 2–ΔΔCt method, with Rpl32 as an 
internal reference. Primer sequences were as follows: Tamm41, forward 5′-TGGAGCCACTACTCCTTCCT, 
reverse 5′-TGATAAGCTTCCCGTCACACC; Pgs1, forward 5′-AGGTTGTGGATGGGATGGTGCA, 
reverse 5′-TCATGGACGTCATCCACTCG; Crls1, forward 5′-CGCCAGCTCGTATGAAAATCC, reverse 
5′-AATCAGGTAGCCCAACACGG; Ptpmt1, forward 5′-ACACCTCGAAGGAATGGAAGAA, reverse 
5′-CTTGAGAGCAAACTGGACTCCT. All abundances were normalized to Rpl32: forward 5′-CCTCTG-
GTGAAGCCCAAGATC, reverse 5′-TCTGGGTTTCCGCCAGTTT.
Isolation of  mouse primary hepatocytes. Mice were anesthetized with pentobarbital, the portal vein was 
cannulated, and the liver was perfused first with solution 1 (Ca+2/Mg+2–free HEPES solution containing 0.5 
mM EGTA) for 5 minutes and then with solution 2 (Ca+2/Mg+2–free HEPES containing 5 mM CaCl2•H2O, 
and type IV collagenase, 0.5–5.0 FALGPA units/mg solid, ≥125 CDU/mg solid) for 10 minutes. Liver 
lobes were submerged in solution 2 and left for an additional 4 minutes at room temperature. Collagenase 
activity was terminated by addition of  10 ml cold DMEM. Tissue was manually dissociated with forceps, 
filtered with 70-μm cell strainers, and spun at 50 g for 2 minutes at 4°C. Pelleted cells were washed twice 
with DMEM/10%FBS followed by centrifugation at 50 g for 2 minutes at 4°C. The cell suspension was 
layered on a Percoll cushion (prepared by mixing 10 ml of  cold Percoll stock with 10 ml of  cold medium) 
and centrifuged at 160 g at for 5 minutes at 4°C. The viable hepatocyte pellet was resuspended in 20 ml of  
DMEM/10% FBS and spun at 50 g for 2 minutes at 4°C. Cells were resuspended in cold DMEM/10% FBS 
and viability was confirmed by trypan blue. Isolated hepatocytes (~1 × 106 cells) were left at –80°C until 
used for lipidomics analysis.
Total hepatic cholesterol concentrations. Livers from mice were homogenized in water (5:1, v/g) with 
2.8- and 1.4-mm zirconium oxide beads in a Precellys Evolution homogenizer at 4°C–10°C. Cholesterol 
was extracted with CHCl3/CH3OH solution and centrifuged (5,000 g, 5 minutes, 4°C). The organic phase 
was recovered, extracted with chloroform, centrifuged (5,000 g, 5 minutes, 4°C) and evaporated using a 
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SpeedVac. Dried samples were resuspended in a kit-supplied buffer (Wako Diagnostics, Cholesterol E kit) 
and analyzed according to the manufacturer’s instructions.
Immunoblotting. Protein extracts were collected from approximately 50 mg frozen liver samples 
in 10 times volume protein lysis buffer containing 20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 
and 1% Triton X-100 at pH 7.5 and supplemented with protease inhibitor cocktail (complete mini 
EDTA-free, Roche) and phosphatase inhibitor cocktail (Sigma-Aldrich, 524629). Immunoblot analysis 
was performed as described previously (20). All blots were blocked with 5% milk/PBST (PBS/0.01% 
Tween-20). The phosphorylated form of  the liver-specific isoform glycogen phosphorylase (p-PYGL) 
was specifically detected using a sheep antibody raised against human glycogen phosphorylase b 
(PYGL)-phosphoserine 15 (acquired from MRC PPU University of  Dundee, S961A; 1:500 in 5% BSA/
PBST). Total PYGL was detected using a rabbit antibody raised against PYGL (St. John’s Laboratory, 
ABIN2564827; 1:2,000 in 5% milk/PBST). p-GS was detected using a rabbit antibody raised against 
pan-GS [Cell Signaling Technology, Phospho-Glycogen Synthase (Ser641) (D4H1B) XP Rabbit mAb 
47043; 1:2,000 in 5% BSA/PBST]. Total GS was detected using a rabbit antibody raised against pan-GS 
[Cell Signaling Technology, Glycogen Synthase (15B1) Rabbit mAb 3886); 1:1,000 in 5% milk/PBST]. 
HMGCS2 protein was detected using a rabbit polyclonal from Santa Cruz Biotechnology [mHMGCS 
Antibody (H-70), sc-33828; 1:1,000 in in 5% milk/PBST]. ABHD6 protein was detected using rabbit 
polyclonal anti-ABDH6 (abcam 133855; 1:2,000). Actin normalizing controls were blotted using a rab-
bit polyclonal anti-actin (Sigma-Aldrich, A2066; 1:1,000 in in 5% milk/PBST) Secondary antibodies 
were all obtained as goat anti-rabbit IgG (Southern Biotech; 1:15,000) conjugated to horseradish per-
oxidase (HRP), with the exception of  p-PYGL, which was a mouse anti-sheep HRP conjugate, Jackson 
Immunoresearch, 213-032-177; 1:10,000 in 5% milk/PBST). Band intensities were measured densito-
metrically using Quantity One software (Bio-Rad).
Serum ketone measurement. Total ketone bodies, βOHB, and AcAc were quantified using standard bio-
chemical assays coupled to colorimetric substrates (Wako).
Histology. For hematoxylin and eosin–stained sections, fixed, paraffin-embedded liver was microtome-
sectioned, stained and photographed using standard methods.
Statistics. Analyses were performed with GraphPad Prism software. Unpaired 2-tailed Student’s t tests, 
or 2- or 1-way ANOVA, with corrections for multiple comparisons, were used as appropriate, as indicated 
within the text and figure legends. Data are presented as the means ± SEM unless otherwise indicated. A 
P value of  less than 0.05 was considered significant.
Study approval. All animal experiments were performed through protocols formally approved by the 
Institutional Animal Care and Use Committees at Sanford Burnham Prebys Medical Discovery Institute-
Lake Nona and the University of  Minnesota.
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